Obika Mikako, Noguchi Hirofumi
Department of General Internal Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
Exp Diabetes Res. 2012;2012:145754. doi: 10.1155/2012/145754. Epub 2011 Oct 27.
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of elevated liver function tests results, after the commonly investigated causes have been excluded, and frequently coexists with type 2 diabetes mellitus (T2DM) because the conditions have common risk factors. As both T2DM and NAFLD are related to adverse outcomes of the other, diagnosis and valuation of fatty liver is an important part of the management of diabetes. Although noninvasive methods, such as biomarkers, panel markers, and imaging, may support a diagnostic evaluation of NAFLD patients, accurate histopathological findings cannot be achieved without a liver biopsy. As it is important to know whether steatohepatitis and liver fibrosis are present for the management of NAFLD, liver biopsy remains the gold standard for NAFLD diagnosis and evaluation. Therefore, new investigations of the pathogenesis of NAFLD are necessary to develop useful biomarkers that could provide a reliable noninvasive alternative to liver biopsy.
非酒精性脂肪性肝病(NAFLD)是排除常见检查病因后肝功能检查结果升高的最常见原因,并且常与2型糖尿病(T2DM)共存,因为这两种疾病有共同的危险因素。由于T2DM和NAFLD均与对方的不良结局相关,因此脂肪肝的诊断和评估是糖尿病管理的重要组成部分。尽管生物标志物、组合标志物和影像学等非侵入性方法可能有助于对NAFLD患者进行诊断评估,但没有肝活检就无法获得准确的组织病理学结果。由于了解是否存在脂肪性肝炎和肝纤维化对于NAFLD的管理很重要,肝活检仍然是NAFLD诊断和评估的金标准。因此,有必要对NAFLD的发病机制进行新的研究,以开发有用的生物标志物,从而提供一种可靠的肝活检非侵入性替代方法。